Zai Lab (ZLAB) said Tuesday that China's National Medical Products Administration has approved its new drug application for Cobenfy for the treatment of schizophrenia in adults.
The approval is supported by the results of a phase 1 and a phase 3 clinical trials in China, as well as three global Emergent clinical trials, the company said.
China Schizophrenia Prevention and Treatment Guidelines already include Cobenfy as a novel treatment for schizophrenia, Zai Lab added.
Shares of the company rose more than 1% in recent pre-bell activity Tuesday.
Price: 17.95, Change: +0.24, Percent Change: +1.36
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments